Some careers span a practice area. Tom Irving’s career has helped define one. With more than 50 years of experience in intellectual property law, Mr. Irving is one of the most recognized pharmaceutical patent practitioners in the United States: a strategist, educator, expert witness, and counselor whose work has shaped how the profession thinks about patent prosecution, Orange Book strategy, and post-grant proceedings in the life sciences.
Thought Leadership
Beyond client work, Mr. Irving has trained thousands of patent professionals throughout his career. For more than 25 years, he served as the principal teacher of the Patent Resources Group’s Chemical Patent Practice course, a comprehensive three-day program taught twice annually, and co-authored the multi-volume treatise used in the course. He originated PRG’s Orange Book and Due Diligence courses and has lectured at law schools including Harvard, Howard, Emory, and Georgia State, as well as institutions in China and at China’s State Intellectual Property Office. He has participated in well over 150 Strafford Webinars on U.S. patent law topics and presents regularly at national bar and trade association meetings, including AIPLA, the Intellectual Property Owners Association, and state bar associations across the country.
Mr. Irving’s contributions to the profession have been widely recognized. He has been named a global IP leader and leading patent prosecutor by Intellectual Asset Management, recognized by The Legal 500 U.S. for patent portfolio management and licensing, and ranked as a patent IP Star by Managing Intellectual Property since 2016. He was inducted into the LMG Life Sciences Hall of Fame and recognized by LMG as Patent Strategy & Management Attorney of the Year for the District of Columbia. In 2022, the American Intellectual Property Law Association named him a Titan of the IP Bar, and the Bar Association of D.C. named him Patent Prosecutor of the Year. In 2025, Howard University School of Law honored him with a Lifetime Achievement Award for IP Social Justice, a recognition that reflects his longstanding commitment to diversity, equity, and inclusion in the profession, particularly his efforts to advance the careers of women, including minority women, in patent law.
Expert Witness Practice
His expert witness practice reflects the trust that litigation teams place in his command of patent prosecution and procedure. In recent years, Mr. Irving has served as an expert in four litigated matters. Among them, he testified on behalf of CureVac on prosecution laches in its litigation against BioNTech and Pfizer, a matter that concluded with CureVac receiving an upfront payment of over $700 million and a royalty on U.S. sales of the COVID-19 vaccine.
Patent Portfolio Strategy & Counseling
Mr. Irving’s practice today is concentrated where the stakes are highest: expert witness testimony in patent litigation, due diligence analysis for pharmaceutical transactions, AIA post-grant proceedings, and counseling on how to build, list, and defend patents in the Orange Book context. He advises both innovative companies protecting branded drugs and parties evaluating pharmaceutical assets in high-value transactions, including due diligence on targets valued at more than $1 billion. His ability to assess the strength of a pharmaceutical patent portfolio and to identify how it can be enhanced to withstand IPR, PGR, and district court challenge is the core of what he offers clients navigating the most consequential decisions in drug development and commercialization.
Representative Experience
Over the course of his career, Mr. Irving has been deeply involved in counseling, due diligence, prosecution, and pre-litigation matters involving some of the most significant drugs in the market, including Kalydeco®, Orkambi®, Tecfidera®, Lantus®, Crestor®, Brilinta®, Jakafi®, Lovenox®, for which he successfully prosecuted a reissue of the foundational low molecular weight heparin patent, and many others across oncology, respiratory medicine, cardiovascular disease, and rare disorders. He has served as lead counsel in numerous patent interferences, reissues, reexaminations, and AIA post-grant proceedings.
Mr. Irving’s practice also encompasses areas he considers persistently underutilized by pharmaceutical patent owners: 35 U.S.C. § 112(f) functional claiming, supplemental examination, claims drafted with infringement in mind, and Sanofi v. Watson-type claim strategies. His counsel in these areas reflects decades of watching patents succeed and fail under challenge, as well as a practitioner’s commitment to building portfolios that hold up when tested.
Work & Education History
Education
- University of Utah (B.A., Chemistry, 1974)
- Duke University School of Law (J.D., 1977)
Admissions & Recognition
- Registered Patent Attorney (USPTO)
- Titan of the IP Bar — American Intellectual Property Law Association (2022)
- Patent Prosecutor of the Year — Bar Association of D.C. (2022)
- LMG Life Sciences Hall of Fame
- Patent Strategy & Management Attorney of the Year for D.C. — LMG Life Sciences
- IP Star — Managing Intellectual Property (2016–present)
- Legal 500 U.S. — Patent Portfolio Management & Licensing
- Lifetime Achievement Award for IP Social Justice — Howard University
- School of Law (2025)


